Abstract #2231

Protective role of Creatine in chronic hepatic encephalopathy developing brain: in vivo longitudinal 1H and 31P-MRS study

Dunja Simicic^1,2,3, Katarzyna Pierzchala^1,2, Olivier Braissant⁴, Stefanita-Octavian Mitrea^1,2, Dario Sessa⁵, Valerie McLin⁵, and Cristina Cudalbu^1,2

¹CIBM Center for Biomedical Imaging, Lausanne, Switzerland, ²Animal Imaging and Technology, EPFL, Lausanne, Switzerland, ³Laboratory of Fuctional and Metabolic Imaging, EPFL, Lausanne, Switzerland, ⁴Service of Clinical Chemistry, University of Lausanne and University Hospital of Lausanne, Lausanne, Switzerland, ⁵Swiss Center for Liver Disease in Children, University Hospitals Geneva, Geneva, Switzerland

Type-C hepatic encephalopathy (CHE) is a complication of chronic liver disease (CLD). It is known that children are more affected by CLD than adult patients. Bile duct ligated rat (BDL) is a model of CLD-induced CHE. It was shown that rats having acquired CLD as pups display more profound neurometabolic disturbances than adults. Cr-treatment showed a positive effect in youngP21 BDL-rats resulting in less pronounced metabolic changes. Our aim was to test whether Cr-supplementation dampens the changes observed in CHE in a longitudinal model of CLD acquired in early childhood-P15 and if these changes are similar to those in P21-rats.

This abstract and the presentation materials are available to members only; a login is required.

Join Here